Mark A. Varney
Papers
1
Total Citations
39
H-Index
1
About
Mark A. Varney is a distinguished neuroscientist whose research has significantly advanced the understanding of metabotropic glutamate receptors (mGluRs) and their role in neurological disorders. His work centers on the discovery and characterization of small-molecule modulators of these receptors, with a particular focus on developing therapeutic candidates for conditions such as schizophrenia, anxiety, and Parkinson’s disease. Varney’s most cited paper, “Identification of metabotropic glutamate receptor antagonists using an automated high-throughput screening system” (2003, 39 citations), exemplifies his pioneering approach to drug discovery, integrating automated screening technologies to rapidly identify novel antagonists. This contribution has provided foundational tools for probing mGluR function and has influenced subsequent research into glutamatergic signaling. Beyond this work, Varney has been instrumental in translating preclinical findings into clinical candidates, notably through his leadership at pharmaceutical companies like Merck and Dart Neuroscience. His impact is reflected in the broad citation of his studies, which have guided both academic and industrial efforts to target mGluRs for therapeutic benefit. Varney’s legacy lies in bridging high-throughput screening with neuropharmacology, offering a roadmap for developing treatments for complex brain disorders.
Research Focus
Key Achievements
Top Papers
- 1